SCHEMBL13445262

SCHEMBL13445262

CNC(=O)CCCCCNC(=O)CCCCCNC(C)=O

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.61
MAPK1 P28482 1/20 0.61
HIF1A Q16665 1/20 0.61
ADRA1A P35348 1/20 0.60
PAOX Q6QHF9 3/20 0.52
CASP2 P42575 1/20 0.50
FAAH O00519 3/20 0.49
NAAA Q02083 1/20 0.47
NAMPT P43490 1/20 0.47
DNM1 Q05193 1/20 0.46
EPHX2 P34913 3/20 0.45
TSHR P16473 1/20 0.44
SLC6A5 Q9Y345 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
ALDH1A1 P00352 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16864576 1.00 KDM4E (0.61) KDM4EMAPK1HIF1AADRA1APAOX
SCHEMBL8373380 0.96 KDM4E (0.67) KDM4EMAPK1HIF1AADRA1APAOX
SCHEMBL19400309 0.96 KDM4E (0.67) KDM4EMAPK1HIF1AADRA1APAOX
SCHEMBL9787810 0.96 KDM4E (0.67) KDM4EMAPK1HIF1AADRA1APAOX
SCHEMBL16303445 0.94 KDM4E (0.62) KDM4EMAPK1HIF1AADRA1APAOX
SCHEMBL23735520 0.92 CASP2 (0.57) ADRA1ACASP2FAAHNAAANAMPT
SCHEMBL23735524 0.92 CASP2 (0.57) ADRA1ACASP2FAAHNAAANAMPT
SCHEMBL23735519 0.90 CASP2 (0.55) ADRA1ACASP2FAAHNAAANAMPT
SCHEMBL23735430 0.90 CASP2 (0.54) CASP2FAAHNAAANAMPTDNM1
SCHEMBL21695694 0.90 KDM4E (0.68) KDM4EMAPK1HIF1AADRA1APAOX

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820805-B2 Conjugate based systems for controlled insulin delivery MERCK SHARP & DOHME LLC (US) 2023-11-21 US disclosed
US-7678295-B2 thermoplastic blends of polyphenylene ethers and polycaprolactam, reinforcing fibers and electroconductive fillers, having tensile strength; used as engine housings having improved appearence; injection molding SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2010-03-16 US disclosed
US-20080090953-A1 thermoplastic blends of polyphenylene ethers and polycaprolactam, reinforcing fibers and electroconductive fillers, having tensile strength; used as engine housings having improved appearence; injection molding GENERAL ELECTRIC COMPANY (US) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11820805-B2 Conjugate based systems for controlled insulin delivery GPR119, INSR, IGF1R KDM4E 2971/4885MAPK1 4342/4885HIF1A 3652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.